Yearly Allergy Shot: Depot Steroid or Pre-Seasonal SCIT?
A 'yearly allergy shot' maps to two different products: (1) a pre-seasonal depot corticosteroid — Kenalog-40 or Depo-Medrol — which is NOT immunotherapy, is NOT disease-modifying, and is discouraged by the AAAAI/ACAAI rhinitis practice parameter; or (2) pre-seasonal SCIT — a short build-up before pollen season each year, far more common in Europe than the US. Neither constitutes the 3–5-year disease-modifying SCIT or daily SLIT that induces lasting allergen-specific tolerance.
6 peer-reviewed sources
A yearly allergy shot is either a depot steroid (Kenalog/Depo-Medrol — AAAAI discourages it) or pre-seasonal SCIT (rare US practice). Disease-modifying allergen immunotherapy requires 3–5 years, not a single annual injection.
The essentials
A 'yearly allergy shot' is not a single procedure — the search intent maps to two different candidates, and neither is standard disease-modifying allergen immunotherapy:
1. Pre-seasonal depot corticosteroid: Kenalog-40 (triamcinolone acetonide, FDA-approved February 1, 1965) or Depo-Medrol (methylprednisolone acetate). This is the allergy shot most patients' parents or grandparents received every spring. Per the Depo-Medrol FDA label: 'an intramuscular dose of 80 to 120 mg may be followed by relief of coryzal symptoms within six hours persisting for several days to three weeks.' This is NOT immunotherapy — it suppresses symptoms via systemic glucocorticoid action without modifying the underlying allergic disease. The AAAAI/ACAAI Joint Task Force rhinitis practice parameter explicitly discourages single administration and contraindicates recurrent use because of HPA-axis and adrenal suppression risk. The British Society for Allergy and Clinical Immunology position: 'the risk-benefit profile for intramuscular corticosteroids is poor.'
2. Pre-seasonal SCIT: a short allergen immunotherapy build-up before pollen season each year, without year-round maintenance — more common in Europe than the US. Per Cox L, Nelson H, Lockey R et al., J Allergy Clin Immunol 2011;127(1 Suppl):S1–S55 (DOI 10.1016/j.jaci.2010.09.034), US allergists predominantly use perennial (year-round) schedules. Pre-seasonal schedules typically begin 8–16 weeks before the patient's primary pollen season; patients skip year-round maintenance. This exists but is not standard US practice.
Curex pairs at-home IgE testing with board-certified allergist review to identify which specific allergens drive a patient's seasonal symptoms — the diagnostic step that determines whether disease-modifying immunotherapy is the right path or whether the patient is misframing depot steroids as 'allergy shots.'
The honest answer: there is no yearly version of disease-modifying allergen immunotherapy. SCIT requires 3–5 years per Cox 2011 PP3 — build-up of 24–28 weekly injections followed by maintenance every 2–4 weeks. Durham SR et al., N Engl J Med 1999;341:468–475 showed 3 years of maintenance produces 4 years of post-discontinuation remission. SLIT requires daily home dosing for 3–5 years. Neither is a once-a-year option.
Ready to skip the surprise bills?
See if at-home allergy shots fit your allergies — a 2-minute quiz, designed by board-certified allergists, with flat monthly pricing and no clinic visits.
- 4.8/5Patient rating
- $129/moFlat pricing
- 50K+Patients treated
- HSA/FSAEligible
Treatment timeline — phase by phase
There is no yearly version of SCIT. The standard three-phase SCIT lifecycle spans 3–5 years and cannot be compressed to an annual injection without forfeiting disease modification.
US conventional SCIT: 24–28 weekly visits escalating allergen dose per Cox 2011 PP3. Pre-seasonal variant (European, uncommon US): shorter build-up beginning 8–16 weeks before pollen season, skipping year-round maintenance. Depot steroids have no build-up schedule — they are a single IM injection.
Conventional SCIT maintenance: every 2–4 weeks for 3–5 years per Cox 2011. Pre-seasonal maintenance: repeated each year before the relevant pollen season. Depot steroids: single annual IM injection, lasting approximately 3 weeks; no ongoing immunological benefit between injections; AAAAI discourages.
Conventional SCIT discontinuation after 3–5 years yields 4-year post-discontinuation remission per Durham 1999 NEJM. Pre-seasonal SCIT durability data is less robust than perennial SCIT. Depot steroids: recurrent annual injections accumulate HPA-axis suppression risk — the AAAAI contraindicates recurrent administration.
Same proven results. No clinic visits.
Curex's at-home allergy shots deliver the same allergen desensitization as clinic SCIT — for a flat $129/month, with no clinic visits and no facility fees.
See if at-home shots are right for youTreatment options side by side
The two candidates behind the 'yearly allergy shot' query are not equivalent — and neither is equivalent to disease-modifying allergen immunotherapy.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
Depot corticosteroids (Kenalog-40 / Depo-Medrol) | |||||
Pre-seasonal SCIT (European variant) | |||||
Conventional SCIT (3–5 year perennial) | |||||
At-home allergy shots (Curex SCIT) |
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
- Efficacy
- Duration
- Cost (5yr)
- Convenience
- Safety
For disease modification rather than annual symptom suppression, Curex delivers real SCIT allergy shots at home for $129/month — a personalized serum sterile-compounded to USP <797> standards, prescribed and overseen by a board-certified allergist, self-administered as one weekly shot with the first dose and every dose change supervised live over Zoom. Not a yearly injection, but the same multi-year immunotherapy that builds allergen-specific tolerance — without the clinic trips.
See if at-home shots are right for youFrequently asked questions
What is a yearly allergy shot?
A 'yearly allergy shot' refers to one of two different products. Most commonly, it describes a pre-seasonal depot corticosteroid — Kenalog-40 (triamcinolone acetonide, FDA-approved 1965) or Depo-Medrol (methylprednisolone acetate) — given as a single intramuscular injection before allergy season. Per the Depo-Medrol FDA label, this provides approximately 3 weeks of symptom relief. Less commonly, it refers to pre-seasonal SCIT — a short allergen immunotherapy build-up before each pollen season, more common in Europe than the US. Neither constitutes the 3–5-year disease-modifying allergen immunotherapy that modifies the underlying allergy per Cox L et al., J Allergy Clin Immunol 2011;127(1 Suppl):S1–S55.
Are depot steroid shots (Kenalog/Depo-Medrol) safe for allergies?
Single-administration depot corticosteroids (Kenalog-40 or Depo-Medrol) are FDA-labeled for allergic rhinitis only in cases 'intractable to adequate trials of conventional treatment,' but the AAAAI/ACAAI Joint Task Force rhinitis practice parameter explicitly discourages single administration and contraindicates recurrent use because of HPA-axis and adrenal suppression risk. The British Society for Allergy and Clinical Immunology states that 'the risk-benefit profile for intramuscular corticosteroids is poor.' Annual use accumulates these systemic risks without providing disease modification — the allergy returns at full severity once the steroid effect wanes. Modern intranasal corticosteroids (fluticasone, mometasone) offer comparable symptom control without systemic side effects.
Why do some patients think one allergy shot per year works?
Depot steroid injections were more widely used in allergy management before modern intranasal corticosteroids became available and before the AAAAI/ACAAI rhinitis practice parameter discouraged their routine use. Patients whose parents or grandparents received annual Kenalog or Depo-Medrol injections in the 1970s–1990s have a cultural memory of a 'yearly allergy shot' that controlled symptoms. The mechanism was systemic glucocorticoid suppression of the inflammatory response — effective for a few weeks but not disease-modifying and increasingly recognized as carrying cumulative risks. Awareness of the AAAAI position has not fully reached lay audiences, which is why this query still generates 30 monthly searches.
What is pre-seasonal allergy immunotherapy?
Pre-seasonal SCIT is a short allergen immunotherapy build-up performed before the relevant pollen season each year, without year-round maintenance. European practice includes this variant, particularly for tree pollen and grass pollen monosensitized patients. The build-up typically begins 8–16 weeks before the patient's primary pollen season, then the patient receives no injections during the off-season. Per Cox L et al., J Allergy Clin Immunol 2011;127(1 Suppl):S1–S55 (DOI 10.1016/j.jaci.2010.09.034), US allergists predominantly use perennial (year-round) schedules — pre-seasonal is recognized but not standard US practice. Durability evidence is less robust for pre-seasonal than for perennial SCIT.
Can the depot steroid shot replace allergy immunotherapy?
No — depot corticosteroids (Kenalog-40, Depo-Medrol) are symptomatic treatments, not allergen immunotherapy. They suppress allergy symptoms for approximately 3 weeks via systemic glucocorticoid action but do not induce allergen-specific tolerance, reduce IgE, generate blocking IgG4, or upregulate regulatory T cells. The underlying allergy returns at full severity after the steroid effect wanes. Disease-modifying treatments are SCIT (3–5 years of injections per Cox 2011) and SLIT (3–5 years of daily drops). Only these two modalities produce the 4-year post-discontinuation remission documented by Durham SR et al., NEJM 1999;341:468–475.
How is the yearly pre-seasonal SCIT different from standard SCIT?
Standard US SCIT is a perennial (year-round) protocol: 24–28 weekly build-up injections followed by maintenance every 2–4 weeks for 3–5 years regardless of season. Pre-seasonal SCIT involves a compressed build-up before each pollen season, skipping year-round maintenance. The practical difference: pre-seasonal patients receive injections only for 2–4 months per year (before the season), then stop until the following year. Durability evidence favors perennial protocols — Durham SR et al., NEJM 1999 and PAT (Möller 2002; Jacobsen 2007) are based on continuous multi-year protocols, not annual cycles. Pre-seasonal SCIT is more common in European practice with different allergen calendars.
What is the AAAAI position on annual steroid allergy shots?
The AAAAI/ACAAI Joint Task Force rhinitis practice parameter explicitly discourages single administration of parenteral corticosteroids for allergic rhinitis and contraindicates recurrent administration. The clinical rationale is the risk of HPA-axis suppression — repeated IM corticosteroids can cause adrenal insufficiency, Cushing's syndrome features, immunosuppression, and osteoporosis. This position reflects the availability of intranasal corticosteroids (fluticasone, mometasone, budesonide) that deliver comparable symptom relief with a topical mechanism and minimal systemic absorption. The AAAAI position is consistent with the British Society for Allergy and Clinical Immunology, which states 'the risk-benefit profile for intramuscular corticosteroids is poor.'
Is there a seasonal version of SLIT drops?
FDA-approved SLIT tablets for grass pollen (Grastek, Oralair) can be taken either year-round or pre-seasonally per FDA labeling — guidelines recommend starting at least 4 months before pollen season and continuing through the season. Some protocols extend to year-round for maximum disease modification. Compounded SLIT drops are typically prescribed year-round by allergists for perennial and seasonal allergens combined. Unlike the single annual depot steroid injection, even 'pre-seasonal' SLIT requires months of daily dosing before and during the relevant season — it is not a single-injection approach. The minimum evidence-based treatment duration for durable SLIT benefit is 3 years per EAACI guidelines.
Related Articles
Allergy Shots vs. Vaccines: Key Differences | Curex
Allergy shots and vaccines are not the same. WHO 1998 endorsed 'allergen vaccine' terminology, but the immune mechanisms differ fundamentally. Co-administration guidance inside.
Read moreAllergy Shot Maintenance Schedule: Cox 2011 Guide | Curex
Allergy shot maintenance: every 2–4 weeks for 3–5 years at ~0.5 mL. 30-min observation continues. Missed-dose rules, Durham 1999 durability, and 42–130 lifetime visit math.
Read moreAllergy Exposure Therapy: Safe vs Unsafe | Curex
Allergy exposure therapy = SCIT or SLIT: controlled escalating allergen doses under allergist care inducing tolerance. Unsupervised exposure is dangerous.
Read moreSeasonal Allergy Shot Guide | Curex SCIT Resource
A seasonal allergy shot is SCIT targeting tree, grass, and weed pollens — not a yearly steroid. Cochrane 51 RCTs: symptom SMD −0.73. Learn the full regimen.
Read moreAllergy Shots Weekly: Do They Have to Be? | Curex Guide
Allergy shots are weekly ONLY during conventional build-up (24–28 visits, 3–6 months). Maintenance shifts to every 2–4 weeks. Cluster compresses to 4–8 weeks. Cox 2011 PP3.
Read moreAllergy Immunotherapy Guide: All Options Compared | Curex
Allergy immunotherapy covers shots, tablets, drops, and OIT. Compare SCIT vs SLIT on efficacy, safety, cost, and FDA status to choose the right route.
Read moreGet your allergy shots — without the clinic.
Curex's flat $129/month covers end-to-end at-home immunotherapy — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
$129/mo flat · No facility fees · HSA/FSA eligible · Cancel anytime
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.